Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
featured
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated

  • 346 views
  • 25 Mar, 2021
  • 1 location
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

glucocorticoids treatment. In a systematic review and meta-analysis, glucocorticoids regimen was the most significant variable explaining the variability between the proportions of ANCA-associated

  • 0 views
  • 23 Jan, 2021
  • 58 locations
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis

The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission and reduces the relapse free survival rate.

  • 0 views
  • 23 Jul, 2021
  • 1 location
Abatacept for the Treatment of Relapsing Non-Severe Granulomatosis With Polyangiitis (Wegener's)

Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe granulomatosis with polyangiitis (Wegener's) (GPA) . Participants will be randomized 1:1 to receive either abatacept 125 mg or placebo administered by subcutaneous injection once a week. Participants will continue …

nasal discharge
churg-strauss syndrome
eosinophilic granulomatosis
urinary sediment
granulomatous inflammation
  • 197 views
  • 28 Apr, 2021
  • 26 locations
Hydroxychloroquine in ANCA Vasculitis Evaluation

(ANCA) Vasculitis, a group of autoimmune diseases. Hydroxychloroquine and is an established, effective, safe and inexpensive therapy, widely used in other autoimmune diseases such as lupus and

  • 0 views
  • 26 Jan, 2021
  • 3 locations
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis

This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved disease activity and/or lower frequency of relapse (compared to historical data and a previously conducted cross sectional …

vasculitis
vitamin d
anca-associated vasculitides
cholecalciferol
anca
  • 32 views
  • 26 Jan, 2021
  • 1 location
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at

  • 0 views
  • 06 Aug, 2021
  • 1 location
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease

Anti-neutrophil cytoplasmic antibodies (ANCA), directed against myeloperoxidase (MPO) and against proteinase 3 (PR3), have a pathogenic role during ANCA (AAV) vasculitis. Glomerular basement

renal impairment
coagulopathy
immunosuppressive agents
  • 0 views
  • 23 Jan, 2021
  • 1 location
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Rationale: Most recent insights in the treatment for patients with ANCA-associated vasculitis (AAV) have demonstrated that 'tailored' maintenance treatment with rituximab (RTX) is effective to

rituximab
cyclophosphamide
  • 0 views
  • 15 Sep, 2021
  • 2 locations